ATLANTA — GeoVax Labs, a biopharmaceutical company that develops vaccines for diseases caused by HIV and other infectious agents, announced the appointment of a vice president of research and development on Jan. 6.
Mark J. Newman, Ph.D., will be responsible for developing GeoVax's therapeutic HIV vaccine initiative and broadening the GeoVax pipeline.
"There is an enormous amount of work to be done to successfully launch our first therapeutic trial as well as to effectively move our preventative vaccine programs forward,” said Harriet Robinson, chief scientific officer.
Newman was vice president of research and development at PaxVax Inc. prior to joining GeoVax. At PaxVax, he led research and preclinical development of adenovirus vectored vaccine candidates. He also has worked on the development of HIV, influenza and cancer vaccines and led active programs on adjuvant and vaccine-delivery technologies.
GeoVax's AIDS vaccines have moved into phase 2a human clinical trials conducted by the HIV Vaccine Trials Network based in Seattle. The company has targeted the launch of its first therapeutic HIV/AIDS vaccine trial for early 2010.